Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1161/CIRCRESAHA.121.318186

http://scihub22266oqcxt.onion/10.1161/CIRCRESAHA.121.318186
suck pdf from google scholar
33983837!8126502!33983837
unlimited free pdf from europmc33983837    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33983837&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid33983837      Circ+Res 2021 ; 128 (10): 1468-1486
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure #MMPMID33983837
  • Njoroge JN; Teerlink JR
  • Circ Res 2021[May]; 128 (10): 1468-1486 PMID33983837show ga
  • Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses worldwide, yet it is an entity with incompletely understood pathophysiology and limited therapeutic options. Patients admitted for ADHF have high in-hospital morbidity and mortality, as well as frequent rehospitalizations and subsequent cardiovascular death. This devastating clinical course is partly due to suboptimal medical management of ADHF with persistent congestion upon hospital discharge and inadequate predischarge initiation of life-saving guideline-directed therapies. While new drugs for the treatment of chronic HF continue to be approved, there has been no new therapy approved for ADHF in decades. This review will focus on the current limited understanding of ADHF pathophysiology, possible therapeutic targets, and current limitations in expanding available therapies in light of the unmet need among these high-risk patients.
  • |Acute Disease[MESH]
  • |Body Fluids/physiology[MESH]
  • |Cardio-Renal Syndrome/complications[MESH]
  • |Cardiotoxins/therapeutic use[MESH]
  • |Comorbidity[MESH]
  • |Heart Failure/diagnosis/*drug therapy/etiology/*physiopathology[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Inflammation Mediators/metabolism[MESH]
  • |Myocardial Contraction/physiology[MESH]
  • |Natriuretic Peptide, Brain/metabolism[MESH]
  • |Patient Discharge[MESH]
  • |Patient Readmission[MESH]
  • |Renin-Angiotensin System/physiology[MESH]
  • |Symptom Assessment[MESH]
  • |Vascular Resistance[MESH]
  • |Vasoconstriction/physiology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box